See more of the story

NEW PRODUCTS

Medtronic Inc., Fridley, said it has submitted the final module of its premarket approval (PMA) application for the IN.PACT Admiral drug-coated balloon to the Food and Drug Administration. The application includes data demonstrating superior clinical outcomes compared with conventional angioplasty, with the lowest rates of repeat procedures (target lesion revascularization) and the highest rate of uninterrupted blood flow (pri­mary patency) at 12 months ever reported for the interventional treatment of ­peripheral artery disease.